Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
NCT ID: NCT04305054
Last Updated: 2025-08-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
315 participants
INTERVENTIONAL
2020-07-01
2026-04-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* About the safety and how well people tolerate pembrolizumab given with other treatments
* How many people have melanoma that responds (gets smaller or goes away) to treatment
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
NCT04303169
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)
NCT04700072
Pembrolizumab in Treating Patients With Advanced Uveal Melanoma
NCT02359851
A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma
NCT02434354
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
NCT02054806
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pembrolizumab + Vibostolimab
Participants will receive pembrolizumab intravenously (IV) plus vibostolimab IV at specified doses on specified days for a total treatment duration of up to approximately 2 years.
Pembrolizumab
Administered via IV infusion at a specified dose on specified days
Vibostolimab
Administered via IV infusion at a specified dose on specified days
Pembrolizumab
Participants will receive pembrolizumab IV at a specified dose on specified days for a total treatment duration of up to approximately 2 years.
Pembrolizumab
Administered via IV infusion at a specified dose on specified days
Coformulation Pembrolizumab/Quavonlimab
Participants will receive coformulation of pembrolizumab and quavonlimab (MK-1308A) IV at a specified dose on specified days for a total treatment duration of up to approximately 2 years.
Pembrolizumab
Administered via IV infusion at a specified dose on specified days
Pembrolizumab/Quavonlimab
Administered via IV infusion at a specified dose on specified days
Coformulation Pembrolizumab/Quavonlimab + Lenvatinib
Participants will receive coformulation of pembrolizumab and quavonlimab IV plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
Pembrolizumab
Administered via IV infusion at a specified dose on specified days
Pembrolizumab/Quavonlimab
Administered via IV infusion at a specified dose on specified days
Lenvatinib
Administered via oral capsule at a specified dose on specified days
Coformulation Favezelimab/Pembrolizumab
Participants will receive cofomulation of favezelimab + pembrolizumab (MK-4280A) IV at specified dose on specified days every 3 weeks (Q3W) for up to approximately 2 years
Favezelimab/Pembrolizumab
Administered via IV infusion at a specified dose on specified days
Coformulation Favezelimab/Pembrolizumab + All-trans Retinoic Acid (ATRA)
Participants will receive coformulation of favezelimab and pembrolizumab IV Q3W for up to 35 cycles, plus ATRA orally (for 3 days surrounding each infusion of MK-4280A, including Days 1, 2, and 3 of Cycle 1 and on Days -1, 1, and 2 of all subsequent cycles).
ATRA
Administered via oral capsule at a specified dose on specified days
Coformulation Favezelimab/Pembrolizumab + Vibostolimab
Participants will receive coformulation of favezelimab and pembrolizumab (MK-4280A) IV and vibostolimab IV at specified doses on specified days for a total treatment duration of up to approximately 2 years.
Vibostolimab
Administered via IV infusion at a specified dose on specified days
Favezelimab/Pembrolizumab
Administered via IV infusion at a specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pembrolizumab
Administered via IV infusion at a specified dose on specified days
Vibostolimab
Administered via IV infusion at a specified dose on specified days
Pembrolizumab/Quavonlimab
Administered via IV infusion at a specified dose on specified days
Lenvatinib
Administered via oral capsule at a specified dose on specified days
Favezelimab/Pembrolizumab
Administered via IV infusion at a specified dose on specified days
ATRA
Administered via oral capsule at a specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has unresectable Stage III or Stage IV melanoma, not amenable to local therapy
* Has been untreated for advanced disease.
* Has provided a tumor biopsy
* If capable of producing sperm, male participants agree to the following during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention (7 days):
* Abstains from penile-vaginal intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agrees to remain abstinent OR
* Uses contraception unless confirmed to be azoospermic
* A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
* Is not a WOCBP OR
* Is a WOCBP and Uses a contraceptive method that is highly effective, with low user dependency, or be abstinent from penile-vaginal intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention. The length of time required to continue contraception for each study intervention is:
* MK-4280A: 120 days
* MK-1308A: 120 days
* MK-7684: 50 days
* MK-3475: 120 days
* Lenvatinib: 30 days
* ATRA: 30 days
* Has adequate organ function
* Has resolution of toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia and Grade 2 neuropathy)
Exclusion Criteria
* Has a known additional malignancy that is progressing or requires active treatment within the past 2 years
* Has known central nervous system (CNS) metastases and/or carcinomatous meningitis
* Has ocular or mucosal melanoma
* Has an active autoimmune disease that has required systemic treatment in the past 2 years
* Has an active infection requiring systemic therapy
* Has known history of human immunodeficiency virus (HIV)
* Has history of Hepatitis B or known Hepatitis C virus infection
* Has a history of (noninfectious) pneumonitis
* Has a history of active tuberculosis (TB)
* Has received prior systemic anticancer therapy within 4 weeks prior to randomization
* Has received prior radiotherapy within 2 weeks of first dose of study intervention
* Has had major surgery \<3 weeks prior to first dose of study intervention
* Has received a live vaccine within 30 days before the first dose of study intervention
* Has participated in a study of an investigational agent within 4 weeks prior to the first dose of study intervention
* Has had an allogeneic tissue/solid organ transplant
* Has a known psychiatric or substance abuse disorder that would interfere with requirements of the study
* Has a pre-existing Grade ≥3 gastrointestinal or non-gastrointestinal fistula
* Has radiographic evidence of encasement of invasion of a major blood vessel, or of intratumoral cavitation
* Has clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study intervention
* Has clinically significant cardiovascular disease within 12 months from first dose of study intervention
* Has urine protein ≥1 g/24-hour.
* Has presence of gastrointestinal condition including malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib
18 Years
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Angeles Clinic and Research Institute ( Site 2009)
Los Angeles, California, United States
UCLA Hematology & Oncology ( Site 2004)
Los Angeles, California, United States
Providence Saint John's Health Center ( Site 2010)
Santa Monica, California, United States
University of Colorado, Anschutz Cancer Pavilion ( Site 2012)
Aurora, Colorado, United States
University of Florida College of Medicine-UF Health Cancer Center/Clinical Trials Office ( Site 2026)
Gainesville, Florida, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 2022)
Baltimore, Maryland, United States
R.J. Zuckerberg Cancer Center ( Site 2032)
Lake Success, New York, United States
NYU Clinical Cancer Center ( Site 2002)
New York, New York, United States
Duke Cancer Institute ( Site 2005)
Durham, North Carolina, United States
Martha Morehouse Tower ( Site 2020)
Columbus, Ohio, United States
Oregon Health & Science University ( Site 2013)
Portland, Oregon, United States
University of Pennsylvania Abramson Cancer Center ( Site 2008)
Philadelphia, Pennsylvania, United States
West Cancer Center - East Campus ( Site 2014)
Germantown, Tennessee, United States
Mays Cancer Center ( Site 2025)
San Antonio, Texas, United States
Inova Schar Cancer Institute ( Site 2011)
Fairfax, Virginia, United States
Clinica Adventista Belgrano-Oncology ( Site 2242)
Caba., Buenos Aires, Argentina
Instituto Alexander Fleming-Alexander Fleming ( Site 2243)
Buenos Aires, Buenos Aires F.D., Argentina
Sanatorio Finochietto ( Site 2245)
Buenos Aires, , Argentina
Calvary Mater Newcastle-Medical Oncology ( Site 2404)
Waratah, New South Wales, Australia
Melanoma Institute Australia ( Site 2402)
Wollstonecraft, New South Wales, Australia
Tasman Oncology Research Pty Ltd ( Site 2403)
Southport, Queensland, Australia
Fiona Stanley Hospital ( Site 2401)
Murdoch, Western Australia, Australia
IC La Serena Research ( Site 2254)
La Serena, Coquimbo Region, Chile
FALP-UIDO ( Site 2251)
Santiago, Region M. de Santiago, Chile
Oncovida ( Site 2257)
Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 2252)
Santiago, Region M. de Santiago, Chile
CIDO SpA-Oncology ( Site 2256)
Temuco, Región de la Araucanía, Chile
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 2261)
Bogotá, Bogota D.C., Colombia
Fundación Valle del Lili ( Site 2265)
Cali, Valle del Cauca Department, Colombia
Hopital La Timone ( Site 2103)
Marseille, Bouches-du-Rhone, France
CHU de Bordeaux- Hopital Saint Andre ( Site 2108)
Bordeaux, Gironde, France
Institut Claudius Regaud ( Site 2105)
Toulouse, Haute-Garonne, France
C.H. Lyon Sud ( Site 2102)
Pierre-Bénite, Rhone, France
A.P.H. Paris, Hopital Saint Louis ( Site 2107)
Paris, , France
Gustave Roussy ( Site 2101)
Villejuif, Île-de-France Region, France
General Hospital of Athens "Laiko"-First Department of Internal Medicine ( Site 2212)
Athens, Attica, Greece
European Interbalkan Medical Center-Oncology Department ( Site 2211)
Thessaloniki, , Greece
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ ( Site 2221)
Szeged, Csongrád megye, Hungary
HaEmek Medical Center ( Site 2703)
Afula, , Israel
Rambam Health Care Campus-Oncology ( Site 2704)
Haifa, , Israel
Hadassah Ein Karem Jerusalem ( Site 2702)
Jerusalem, , Israel
Rabin Medical Center-Oncology ( Site 2705)
Petah Tikva, , Israel
Chaim Sheba Medical Center ( Site 2701)
Ramat Gan, , Israel
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 2399)
Milan, , Italy
Istituto Europeo di Oncologia ( Site 2301)
Milan, , Italy
Istituto Nazionale Tumori Fondazione Pascale ( Site 2302)
Napoli, , Italy
Istituto Oncologico Veneto IRCCS ( Site 2355)
Padua, , Italy
Policlinico Le Scotte - A.O. Senese ( Site 2377)
Siena, , Italy
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 2233)
Warsaw, Masovian Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 2231)
Gdansk, Pomeranian Voivodeship, Poland
CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 2865)
Port Elizabeth, Eastern Cape, South Africa
Steve Biko Academic Hospital-Medical Oncology ( Site 2862)
Pretoria, Gauteng, South Africa
LIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 2861)
Pretoria, Gauteng, South Africa
Sandton Oncology Medical Group (Pty) Ltd-Research ( Site 2863)
Sandton, Gauteng, South Africa
Cape Town Oncology Trials ( Site 2864)
Cape Town, Western Cape, South Africa
HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Site 2801)
Barcelona, Catalonia, Spain
Hospital Universitario Ramón y Cajal ( Site 2802)
Madrid, Madrid, Comunidad de, Spain
Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 2603)
Geneva, Canton of Geneva, Switzerland
CHUV Centre Hospitalier Universitaire Vaudois ( Site 2602)
Lausanne, Canton of Vaud, Switzerland
Universitaetsspital Zuerich ( Site 2601)
Zuerich Flughafen, Canton of Zurich, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-3475-02B
Identifier Type: OTHER
Identifier Source: secondary_id
KEYMAKER-U02
Identifier Type: OTHER
Identifier Source: secondary_id
2023-506313-21-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1293-5644
Identifier Type: REGISTRY
Identifier Source: secondary_id
2019-003977-24
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
3475-02B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.